American Oriental Bioengineering, Inc. (AOBI) Stock Price & Analysis

American Oriental Bioengineering, Inc. Company Overview

American Oriental Bioengineering, Inc. (AOBI), trading on the OTC Other tier, operates within the biotechnology sector, developing and marketing pharmaceutical and nutraceutical products. While specific product details are limited in available information, companies in this sector often focus on specialized treatments or supplements. A potential strength lies in the general growth prospects of the nutraceuticals market; however, companies on the OTC Other tier typically carry higher risks due to less stringent reporting requirements and lower liquidity. Investors should closely monitor AOBI's financial filings and announcements for updates on product development and regulatory compliance.

American Oriental Bioengineering, Inc. develops, manufactures, and commercializes pharmaceutical and healthcare products in China. Their portfolio includes prescription drugs, over-the-counter medications, and nutraceutical products, catering to a wide range of health needs.

Key Facts

• Sector: Healthcare
• Industry: Biotechnology
• Headquarters: Beijing, CN
• CEO: Shujun Liu
• Employees: 3719

What American Oriental Bioengineering, Inc. Does

Develops and manufactures prescription pharmaceutical products.,Offers over-the-counter (OTC) pharmaceutical products.,Provides nutraceutical products, including soybean peptide-based items.,Engages in the wholesale and retail of pharmaceutical and nutraceutical products.,Sells products directly to hospitals, clinics, and pharmacies.,Distributes products through supermarkets, fitness centers, and specialty stores.

Business Model

Develops and manufactures pharmaceutical and nutraceutical products.,Sells products through direct sales and distributors.,Targets hospitals, clinics, pharmacies, supermarkets, and specialty stores.,Generates revenue from prescription drugs, OTC medications, and nutraceuticals.

Key Competitors

Arco US Corp., Code Chain New Continent Ltd., Encode Ideas, Inc., Longboard, Inc., MyMD Pharmaceuticals, Inc.

AOBI Investment Analysis

Investment Thesis

Investing in American Oriental Bioengineering, Inc. presents a high-risk, high-reward scenario. The company operates in the Chinese pharmaceutical market, which offers significant growth potential but also faces regulatory and competitive pressures. AOBI's negative profit margin of -41.2% raises concerns about its financial sustainability. Key growth catalysts include expanding distribution networks and introducing new products. The company's success hinges on its ability to improve profitability, navigate the complex Chinese regulatory landscape, and effectively compete with both domestic and international pharmaceutical companies. The absence of a dividend yield further emphasizes the speculative nature of this investment. Investors should closely monitor AOBI's financial performance and market dynamics before making investment decisions.

Growth Catalysts

• Upcoming: Potential regulatory approvals for new pharmaceutical products.
• Ongoing: Expansion of distribution network in China.
• Ongoing: Development and launch of new nutraceutical products.
• Ongoing: Strategic partnerships with other healthcare companies.

Risk Factors

• Potential: Regulatory changes in the Chinese pharmaceutical market.
• Ongoing: Intense competition from domestic and international companies.
• Ongoing: Price controls and reimbursement pressures affecting profitability.
• Potential: Fluctuations in raw material costs impacting gross margins.

Analyst Coverage for AOBI

AOBI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

Questions & Answers

Is AOBI a good stock to buy?

Whether AOBI is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate American Oriental Bioengineering, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice—consult a qualified advisor before investing.

How often is AOBI data updated?

AOBI's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update as market data refreshes.

What are the risks of investing in AOBI?

Risk categories for AOBI include market risk, company-specific risk, financial risk (debt, cash burn), and macroeconomic risk. Review the Risk Factors section for details specific to this stock. All investments carry risk of loss.